Mivebresib
Modify Date: 2024-01-02 07:16:38
Mivebresib structure
|
Common Name | Mivebresib | ||
|---|---|---|---|---|
| CAS Number | 1445993-26-9 | Molecular Weight | 459.466 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 608.9±65.0 °C at 760 mmHg | |
| Molecular Formula | C22H19F2N3O4S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 322.0±34.3 °C | |
Use of MivebresibMivebresib is a potent and orally available bromodomain and extraterminal domain (BET) bromodomain inhibitor. Mivebresib binds to BRD4 with a Ki of 1.5 nM. |
| Name | N-[4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide |
|---|---|
| Synonym | More Synonyms |
| Description | Mivebresib is a potent and orally available bromodomain and extraterminal domain (BET) bromodomain inhibitor. Mivebresib binds to BRD4 with a Ki of 1.5 nM. |
|---|---|
| Related Catalog | |
| Target |
IC50: 1.5 nM (BET)[1] |
| In Vitro | Mivebresib inhibit DHT-stimulated transcription of AR target genes without significant effect on AR protein expression. In addition to blocking the transcription activation downstream of AR, Mivebresib is also a potent inhibitor of MYC and the TMPRSS2-ETS fusion proteins[1]. |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 608.9±65.0 °C at 760 mmHg |
| Molecular Formula | C22H19F2N3O4S |
| Molecular Weight | 459.466 |
| Flash Point | 322.0±34.3 °C |
| Exact Mass | 459.106445 |
| LogP | 3.91 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.647 |
| Storage condition | -20℃ |
| N-[4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide |
| N-[4-(2,4-Difluorphenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethansulfonamid |
| N-[4-(2,4-Difluorophénoxy)-3-(6-méthyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phényl]éthanesulfonamide |
| Ethanesulfonamide, N-[4-(2,4-difluorophenoxy)-3-(6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]- |
| Mivebresib |
| ABBV-075 |